Interpace Diagnostics (NASDAQ: IDXG) announced today that Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world's leading health care diagnostics company, will begin offering Interpace's new ThyraMirTM microRNA classifier test. Physicians will be able to order ThyraMir through LabCorp, in addition to Interpace's ThyGenX® oncogene panel, which LabCorp already offers. These innovative assays provide enhanced options for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
Studies show that the combination of the two molecular tests provides unprecedented high sensitivity and specificity, enabling physicians to either rule in or rule out malignancy in thyroid nodules initially deemed indeterminate by standard cytology. In addition to providing more precise diagnostic information, performing the tests together will in many cases eliminate the need for patients to undergo a second fine needle biopsy to collect the specimen typically needed for further tests.
"This agreement with LabCorp expands the reach of our molecular diagnostic tests for indeterminate thyroid nodules, and is a significant step in increasing access to the unmatched benefits of our molecular thyroid products. The ThyGenX and ThyraMir assays will provide physicians with data to help change treatment decisions and will improve the health and lives of patients," commented Jack Stover, Interim Chief Executive Officer of Interpace Diagnostics.
LabCorp is the preferred national laboratory offering ThyGenX and ThyraMir, while Interpace continues to drive sales and marketing, conduct clinical research, and perform the assays in its CLIA certified and CAP accredited laboratory. Customers may contact their LabCorp sales representative for information on how to order ThyGenx and ThyraMir through their existing account.
Interpace Diagnostics Group, Inc.